Allergan Breast Implants

If you received textured or smooth implants manufactured by Allergan, you may be affected by this class action lawsuit. Please fill out the form below to get in touch with us. Joining our contact list creates no financial obligation and we will keep all the information that you provide to us confidential.

Case Name: Bunsko v. Allergan Inc., SCBC No. 196308, Vancouver Registry (the “BC Allergan Class Action”)
Kibalian v. Allergan PLC, CV-19-00620507-00CP (“the ON Allergan Class Action”)
Basal v. Allergan Inc., No: 500-06-000966-198 (“the QC Allergan Class Action”)
Together the BC Allergan Class Action, the ON Allergan Class Action, the QC Allergan Class Action will be called “the National Allergan Class Actions”
Court: The BC Allergan Class Action was filed in the Supreme Court of British Columbia
Date Filed: The BC Allergan Class Action was filed May 31, 2019.
Class Members: Collectively the class has been defined as “All persons residing in Canada who were implanted with breast implants manufactured and distributed by Allergan plc and several of its affiliates”.

This proposed class action arises from Allergan’s alleged failure to disclose health risks associated with their breast implants, sold in Canada, including in British Columbia. Class action lawsuits were commenced in British Columbia, Ontario, and Quebec, collectively the National Allergan Class Actions.

Health Canada has recently suspended Allergan’s license for its Biocell breast implants. The full details of the Health Canada recall can be found here.

Our firm is seeking compensation for persons who underwent implant surgery with Allergan breast implants without being provided with full and adequate disclosure of the risks associated with the implants, including the risk of Anaplastic Large Cell Lymphoma (“BIA-ALCL”) and for related financial losses associated with these health issues.

To access the court documents, click on the links below:
• Notice of Civil Claim (BC)
• Statement of Claim (ON)
• Application to Authorize (QC)

A certification hearing has been scheduled in the ON Action for Dec 1-3, 2021.

For further information concerning this action, please contact Natalie Beaupré-Fulton at 604-682-3771 or email